High hopes for cannabinoid agonists in the treatment of rheumatic diseases

There are two well-characterised isoforms of cannabinoid receptor; CB1 and CB2 and of these CB2 is under active investigation as a potential target for treatment of the chronic pain associated with widespread and intractable joint diseases osteoarthritis and rheumatoid arthritis. The recent report by Fukuda et al (BMC Musculoskelet Disord15: 275, 2014) in BMC Musculoskeletal Disorders investigates the efficacy of a selective CB2 agonist, JW133, in both in vitro and in vivo models of rheumatoid arthritis and provides encouraging data. The report shows that JW133 inhibits expression of the CCL2 cytokine, osteoclastogenesis and reduces histological indicators of joint degeneration. Each of these could potentially contribute to beneficial analgesic effects in a therapeutic context.

• Publication year

  2014

• Venue

  BMC Musculoskeletal Disorders

• Publication date

  2014-12-04

• Fields of study

  Medicine

• Identifiers
  DOI 10.1186/1471-2474-15-410PMID 25477254PMCID 4289380
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Are cannabidiol and Δ9‐tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review

  2015cited by this paper
• Activation of GPR18 by cannabinoid compounds: a tale of biased agonism

  2014cited by this paper
• Cannabinoid receptor 2 as a potential therapeutic target in rheumatoid arthritis

  2014influential reference
• The global burden of rheumatoid arthritis: estimates from the Global Burden of Disease 2010 study

  2014cited by this paper
• Reflecting on the global burden of musculoskeletal conditions: lessons learnt from the Global Burden of Disease 2010 Study and the next steps forward

  2014cited by this paper
• Screening the role of pronociceptive molecules in a rodent model of endometriosis pain.

  2014cited by this paper
• Duality of fibroblast-like synoviocytes in RA: passive responders and imprinted aggressors

  2013cited by this paper
• Cannabinoid CB2 Receptors Regulate Central Sensitization and Pain Responses Associated with Osteoarthritis of the Knee Joint

  2013cited by this paper
• The Future of Osteoarthritis Therapeutics: Emerging Biological Therapy

  2013cited by this paper
• Characterisation of fibroblast-like synoviocytes from a murine model of joint inflammation

  2013cited by this paper
• Ion Channels and Osteoarthritic Pain: Potential for Novel Analgesics

  2013cited by this paper
• Osteoarthritis as an inflammatory disease (osteoarthritis is not osteoarthrosis!).

  2013cited by this paper
• Minocycline influences the anti-inflammatory interleukins and enhances the effectiveness of morphine under mice diabetic neuropathy.

  2013cited by this paper
• The role of synovitis in osteoarthritis pathogenesis.

  2012cited by this paper
• Platelet-rich plasma loaded hydrogel scaffold enhances chondrogenic differentiation and maturation with up-regulation of CB1 and CB2.

  2012cited by this paper
• Effects of cannabinoids and cannabinoid‐enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes

  2011cited by this paper
• The Emerging Chondrocyte Channelome

  2010cited by this paper
• Tanezumab for the treatment of pain from osteoarthritis of the knee.

  2010cited by this paper
• The Wisdom of the Body; A Contemporary View

  2010cited by this paper
• The role of synovitis in pathophysiology and clinical symptoms of osteoarthritis

  2010cited by this paper
• In vitro expression of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in cultured equine articular cells.

  2010cited by this paper
• Synovial fibroblasts spread rheumatoid arthritis to unaffected joints

  2009cited by this paper
• The contribution of the synovium, synovial derived inflammatory cytokines and neuropeptides to the pathogenesis of osteoarthritis.

  2009cited by this paper
• Endocannabinoid signaling in microglial cells.

  2009cited by this paper
• New perspective in osteoarthritis: the OPG and RANKL system as a potential therapeutic target?

  2009cited by this paper
• Osteoclastogenesis--current knowledge and future perspectives.

  2008cited by this paper
• The orphan receptor GPR55 is a novel cannabinoid receptor

  2007cited by this paper
• Novel cannabinoid receptors

  2007cited by this paper
• Peripheral cannabinoid receptor, CB2, regulates bone mass.

  2006cited by this paper
• Allosteric Modulation of the Cannabinoid CB1 Receptor

  2005cited by this paper
• Interleukin-32, CCL2, PF4F1 and GFD10 are the only cytokine/chemokine genes differentially expressed by in vitro cultured rheumatoid and osteoarthritis fibroblast-like synoviocytes.

  2005cited by this paper
• Nonpsychotropic Cannabinoid Receptors Regulate Microglial Cell Migration

  2003cited by this paper
• Identification of Naf1/ABIN‐1 among TNF‐α‐induced expressed genes in human synoviocytes using oligonucleotide microarrays

  2003cited by this paper
• Introduction and WHO perspective on the global burden of musculoskeletal conditions.

  2002influential reference
• Induction of collagenase-3 (MMP-13) in rheumatoid arthritis synovial fibroblasts.

  2000cited by this paper
• Fibroblast biology: Role of synovial fibroblasts in the pathogenesis of rheumatoid arthritis

  2000cited by this paper
• 3-(1',1'-Dimethylbutyl)-1-deoxy-delta8-THC and related compounds: synthesis of selective ligands for the CB2 receptor.

  1999cited by this paper
• Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system.

  1998influential reference
• Pharmacology of cannabinoid receptors.

  1995influential reference
• Molecular characterization of a peripheral receptor for cannabinoids

  1993cited by this paper
• Enhanced expression of the N-myc gene in Wilms' tumors.

  1986cited by this paper

• Dose‐Dependent Cannabidiol‐Induced Elevation of Intracellular Calcium and Apoptosis in Human Articular Chondrocytes

  2019cites this paper
• Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update

  2016cites this paper